The NZM2410-derived Sle1a lupus susceptibility locus induces activated autoreactive CD4 þ T cells and reduces the number and function of Foxp3 þ regulatory T cells (Tregs). In this study, we first showed that Sle1a contributes to autoimmunity by increasing antinuclear antibody production when expressed on either NZB or NZW heterozygous genomes, and by enhancing the chronic graft versus host disease response indicating an expansion of the autoreactive B-cell pool. Screening two nonoverlapping recombinants, the Sle1a.1 and Sle1a.2 intervals that cover the entire Sle1a locus, revealed that both Sle1a.1 and Sle1a.2 were necessary for the full Sle1a phenotype. Sle1a.1, and to a lesser extent Sle1a.2, significantly affected CD4 þ T-cell activation as well as Treg differentiation and function. Sle1a.2 also increased the production of autoreactive B cells. As the Sle1a.1 and Sle1a.2 intervals contain only 1 and 15 known genes, respectively, this study considerably reduces the number of candidate genes responsible for the production of autoreactive T cells. These results also show that the Sle1 locus is an excellent model for the genetic architecture of lupus, in which a major obligate phenotype results from the coexpression of multiple genetic variants with individual weak effects.
Introduction
Genetic analyses conducted with systemic lupus erythematosus (SLE) patients and murine models have revealed that SLE susceptibility results from a large number of polymorphisms, each of which results in a weak phenotypic effect. 1 Among the murine quantitative traits loci associated with SLE, 2 Sle1 on telomeric chromosome 1 provided the strongest linkage to disease in the NZM2410 model. 3 This NZW-derived locus overlaps with several other lupus susceptibility quantitative traits loci: NZM2328-derived Fcgnz1, 4 NZB-derived Nba2, 5 BXSB-derived Bxs3, 6 129-derived Sle16 7 and MRL-derived Mag. 8 Furthermore, this region is syntenic to 1q23, a region of confirmed linkage with human SLE. 9 Overall, this region has the strongest non-major histocompatibility complex concordance among lupus models and humans, and it is very likely that at least some of the genetic polymorphisms responsible for these linkages are shared among them. A congenic analysis has shown that either Sle1 NZW or Sle16 129 expression on a C57BL/6 (B6) background induced the production of antinuclear autoantibodies (ANAs), 10, 11 and that the Sle1 phenotype was mediated though intrinsic defects in both B and T cells. 12 Sle1 congenic recombinants have revealed that the production of anti-chromatin antibodies (Abs) was mediated by at least three independent loci: Sle1a, Sle1b and Sle1c. 13 Sle1b results from polymorphisms in the signaling lymphocyte activation molecule (SLAM) family gene cluster.
14 Polymorphisms in Cr2 are associated with some of the Sle1c phenotypes. 15 On the basis of this work, an association between Cr2 polymorphisms and disease has been shown in lupus patients. 16, 17 Sle1a, as well as the centromeric portion of Sle1c, are associated with the production of activated autoreactive CD4 þ T cells that provided help to B cells to secrete anti-chromatin immunoglobulin G (IgG). 18, 19 Further analysis showed that Sle1a regulates the number and function of regulatory CD4 þ T cells (Tregs) not only through the Tregs themselves, but also by decreasing the effector T-cell (Teff) responses to Tregs, and by impairing the ability of dendritic cells to support suppression through the production of interleukin-6. 20, 21 In this study we report the analysis of congenic recombinants showing that the Sle1a CD4 þ T cells phenotypes map to two independent loci, Sle1a.1 and Sle1a.2, each contributing to overlapping but distinct autoimmune alterations. The Sle1a.1 interval contains only one gene, and the Sle1a.2 interval contains 15 known genes, which puts us considerably closer to the identification of the genetic variants responsible for the associated autoimmune phenotypes.
Results
Sle1a contributes to autoantibody production Sle1 induces the production of anti-chromatin IgG and triggers autoimmune pathology when expressed on an NZW heterozygous genome. 22 Sle1c by itself leads to a very modest autoAb production, but significantly increases autoAb production and renal pathology when expressed on a NZB heterozygous genome. 23 Using the same strategy for Sle1a, we compared (NZB Â B6.Sle1a)F1 and (NZW Â B6.Sle1a)F1 with (NZB Â B6)F1 and (NZW Â B6)F1 mice, respectively, up to 12 months of age. (NZW Â B6.Sle1a)F1 mice produced significantly more anti-chromatin IgG than (NZW Â B6) F1 controls (Figure 1a) , and the amount of anti-doublestranded DNA (dsDNA) IgG was significantly greater in both (NZB Â B6.Sle1a)F1 and (NZW Â B6.Sle1a)F1 mice when compared with controls ( Figure 1b) . Interestingly, (NZB Â B6.Sle1a)F1 mice produced significantly more anti-dsDNA IgG than the (NZW Â B6.Sle1a)F1, whereas the reverse was observed for anti-chromatin IgG (Figures  1c and d) . This difference could be because of the differential effect of NZW/NZW versus NZW/NZB Sle1a alleles or because of differences between the NZB and NZW alleles on the rest of the genome. No significant renal pathology was observed in either (NZB Â B6.Sle1a)F1 or (NZW Â B6.Sle1a)F1 mice. Nonetheless, this experiment shows that Sle1a expression significantly enhances antinuclear autoAb production.
To better define the role of Sle1a in autoimmunity, we used the chronic graph versus host disease (cGVHD) model in which I-Ab-mismatched CD4 þ T cells transferred from B6.bm12 mice provide bystander help to resident autoreactive B cells that are otherwise tolerized. 24 B6.bm12 splenocytes induced significantly more anti-chromatin and anti-dsDNA IgG, lymphoid expansion, expansion of T1 B cells at the expense of follicular B cells and T-and B-cell activation in B6.Sle1a than in B6 mice (Figures 2a-f ). C3 and IgG deposition was also significantly increased in B6.Sle1a when compared with B6 glomeruli (Figures 2g and j) . These results indicate that Sle1a expression expands the pool of autoreactive B cells, which, in this model, require interactions with CD4 þ T cells during their development. 25 To determine whether Sle1a enhanced cGVHD through T or B cells, we induced cGVHD in mixed bone marrow (BM) chimeras reconstituted with a mixture of BM from two of the B6.Sle1a.Tcrb
or B6.Igh6 strains in such a way that the T-and B-cell origin was from either Sle1a or B6. Activation of either CD4 þ T cells or B cells in these chimeras tracked with the Sle1a origin of each of these cell types (data not shown). The chimeras in which both T and B cells expressed Sle1a produced significantly more anti-dsDNA IgG (Figure 2h ) and showed an increase in spleen weight (data not shown) when compared with chimeras in which both T and B cells were of B6 origin. The expression of Sle1a in B cells only, but not in T cells, showed a similar trend. A significant difference was obtained when all chimeras were grouped according to the origin of their B cells, either Sle1a or B6, but not their T cells (Figure 2i ), suggesting an intrinsic B-cell effect of Sle1a expression. Taken together, these data showed that Sle1a increases the number of autoreactive B cells that respond to alloreactive T-cell help, at least partially in an intrinsic B-cell manner.
More than one gene contributes to Sle1a ANA production The entire Sle1a interval is covered by the combination of the Sle1a.1 and Sle1a.2 intervals (Figure 3 ). The Sle1a.1 interval contains only one gene, Pbx1, whereas the Sle1a.2 interval contains 15 known genes and 3 ESTs or predicted peptides, with 7 of them expressed in CD4 þ T cells, 9 expressed in B cells and 11 expressed in myeloid cells (Table 1 ). The Sle1a.1 and Sle1a.2 intervals poten- Sle1a regulation of T-cell function requires two sub-loci CM Cuda et al tially overlap between rs31413434 and rs30711102 (o100 Kb) upstream of the Pbx1 transcriptional start site, in a region that does not contain any gene. The Sle1a.2 interval extends on the telomeric end beyond the Sle1a interval, resulting in the Fcgr2b gene having the B6 and NZW alleles in B6.Sle1a and B6.Sle1a.2, respectively. 26 The whole Sle1a interval is associated with a low but significant production of anti-chromatin IgG. 13 However, both 9-to 12-month-old B6.Sle1a.1 and B6.Sle1a.2 mice produced anti-chromatin IgG to the same level as agedmatched B6 controls (data not shown). A robust ANA staining was observed in 80% of the 9-to 12-month-old B6.Sle1a sera, whereas only 25% on the B6.Sle1a.2 sera and no B6.Sle1a.1 sera showed nuclear staining ( Figure 2k ). The ANA titers reflected the same pattern with the only significant difference existing between B6.Sle1a and B6 (median titer: 160 vs 40, Po0.01). Sle1a regulation of T-cell function requires two sub-loci CM Cuda et al
We observed the same result for spleen weight, which was significantly higher in B6.Sle1a than B6 mice, but similar between B6.Sle1a.1, B6.Sle1a.2 and B6 (Table 2) . Peripheral differentiation and activation of B cells was affected by Sle1a expression, with significant accumulation of T1 transitional B cells and increased expression of CD86 and CD22. Neither the increased T1/follicular B-cell ratio nor increased CD86 expression mapped to either Sle1a.1 or Sle1a.2, whereas the increased CD22 expression mapped to both Sle1a.1 and Sle1a.2 (Table 2) . When cGVHD was induced in the Sle1a sub-congenic strains, the B6.Sle1a.1 phenotypes were equivalent to B6, whereas the B6.Sle1a.2 phenotypes were similar to that of B6.Sle1a (Figures 2a-f ). This result indicates that the 
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Pre B-cell leukemia transcription factor 1
RefSeq peptide predicted Cdca1
Cell division cycle associated 1
Regulator of G-protein signaling 5 Rsg4
Regulator of G-protein signaling 4
Discoidin domain receptor family, member 2
Nitric oxide synthase 1 adaptor protein
Activating transcription factor 6 À + + Dusp12
Dual specificity phosphatase 12 Human expression (no data available for mouse). Sle1a increased CD4 þ T-cell proliferation and activation maps to both Sle1a.1 and Sle1a.2 Sle1a expression significantly increases CD4 þ T-cell proliferation and activation, 18 including ICOS expression. 20 Expression of either Sle1a.1 or Sle1a.2 significantly increased spontaneous in vivo proliferation of the CD4 þ T cells (Figures 4a and b) . This difference was observed as early as when 2 to 3 months old, which most likely indicates a primary defect. Moreover, no difference was observed for B-cell proliferation (data not shown), indicating that it does not correspond to a generalized lymphoproliferation. Increased activation was also detected in both Sle1a.1 and Sle1a.2 CD4 þ T cells, with increased CD69 expression when either 2 to 3 months old ( Figure 4c ) or when 8-12 months old (data not shown), and expanded CD44 hi CD62L À memory over CD44 lo CD62L þ naive CD4 þ T cells in the older mice ( Figure 4d ). For each of these phenotypes, the results obtained with Sle1a were similar to either that of Sle1a.1 or Sle1a.2, indicating that the two sub-loci did not have an additive effect. However, increased ICOS expression only mapped to Sle1a.1 (Figure 4e ). These results clearly show that both sub-loci contribute to increased CD4 þ T-cell proliferation and general activation, and that, in addition, Sle1a.1 upregulates ICOS expression. Figures 5a and b) . Tregs are CD4
þ , a T-cell subset that is significantly decreased in B6.Sle1a mice, indicating that Sle1a is associated with a higher proportion of recently activated CD4 þ CD25 þ T cells. 20 This phenotype also mapped to both Sle1a.1 and Sle1a.2 ( Figure 5c ). Overall, these results indicate that both Sle1a.1 and Sle1a.2 contribute to a reduced Treg compartment.
We have previously reported that Sle1a Tregs are no longer suppressive at low Treg/Teff ratios, indicating that the B6.Sle1a CD4 Figure 5e , there was only a small reduction in the inhibitory capacity of B6.Sle1a.1 and B6.Sle1a.2 Sle1a (Figures 5f and g ). Expression of either Sle1a.1 (Figure 5f 
Using the experimental colitis model, 27 we have shown that Sle1a Tregs did not suppress tissue inflammation induced by either B6 or B6.Sle1a Teffs, and that Sle1a Teffs were resistant to suppression. 20 We
CD25
À Teffs from B6 or congenic (B6.Sle1a, B6.Sle1a.1 or B6.Sle1a.2) mice in the presence or absence of CD4 þ CD25 þ Tregs from these mice. As expected, the B6 Teff-induced colitis, defined by a 15% body weight loss and by histology, was completely abrogated by B6 Tregs (Figure 6a) , and the most severe colitis was induced by Sle1a Teff alone (Figure 6b) . A spectrum of severity was observed in mice receiving Sle1a.1 or Sle1a.2 Teffs and Tregs in combination with B6 T cells. The lesser involved colons showed inflammation limited to the crypts (cryptitis) and lamina propria. Increasing inflammation involved the muscularis mucosa and inner submucosal connective tissue stroma. The most severe inflammation involved the muscularis propria, submucosal stroma and serosa. The capillaries and venules in each layer with inflammation showed margination and congestion with mononuclear cells and swelling. Cryptitis was primarily lymphocytic but higher-grade specimens also had focal neutrophilic crypt abscesses. More epithelioid inflammation was also present in the higher-grade lesions in the lamina propria and deeper layers with nodules and occasional multinucleated epithelioid giant cells (Figure 6b (Figure 6g ). Impaired Sle1a.2 Tregs were detected clinically with body weight loss (data not shown), but not by histology (Figure 6g ), indicating that this functional impairment was not as severe as for Sle1a.1. Sle1a.1 Teffs were resistant to suppression by B6 Tregs to a similar level as Sle1a Teffs (Figure 6g ). In contrast, mice reconstituted with B6 Tregs/Sle1a.2 Teffs or B6 Tregs/B6 Teffs had equivalent scores, indicating that Sle1a.2 does not increase Teff inflammatory functions in vivo.
In addition to colitis, B6.Rag mice injected with Sle1a Teffs develop nephritis, 20 which was characterized by up to 30 interstitial inflammatory foci per kidney (Figure 6d ). The foci were oval with histologically normal cortex between foci, and generally specimens with more foci also had larger individual foci. The character of the renal inflammation was remarkably similar to the colon mucosa in three respects. (1) The interstitium was expanded by primarily lymphocytes and monocytes and edema. This involved both the fibrous interstitial space and the peritubular capillaries (capillaritis). (2) The tubular epithelial cells were infiltrated with lymphocytes (tubulitis) with characteristic halos (Figure 6f) . 28 ( 3) The larger foci had epithelioid character with occasional multinucleated epithelioid giant cells (Figure 6d ). Furthermore, colitis severity and the number of renal foci were highly correlated (R ¼ 0.80, P ¼ 0.0002). The B6.Rag kidneys from mice reconstituted with B6 Teff/B6 Treg were similar to that of unmanipulated B6 mice (Figures 6c and e) . Sle1a Teffs induced a significantly higher number of renal foci when compared with B6 Teffs (Figures 6d and f) , but neither Sle1a.1 nor Sle1a.2 Teffs were able to reproduce this phenotype (Figure 6h ). Sle1a, and to a lesser extent Sle1a.1 and Sle1a.2 Tregs, were defective in preventing renal infiltrates induced by B6 Teffs (Figure 6i ). Finally, renal infiltrates induced by Sle1a Teffs were only partially suppressed by B6 Tregs, whereas those induced by either Sle1a.1 or Sle1a.2 Teffs were completely suppressed by B6 Tregs (Figure 6i ). Overall, these in vivo results determined that expression of both Sle1a.1 and Sle1a.2 is necessary to achieve Sle1a Treg and Teff defects, with Sle1a.1 providing the greater contribution. It also showed that Sle1a T cells induce a significant level of renal inflammation, which may have a significant role in the disease process of lupus nephritis. 20 The same mixed BM chimera approach for Sle1a.1 and Sle1a.2 produced similar results (Figure 7) . The increased activation of CD4 þ T cells (Figure 7a ) and the decreased percentage of CD4
Tregs (Figure 7b ) were again completely reproduced by Sle1a.1 or Sle1a.2 BM-derived cells, and in the mixed chimeras containing both congenic and normal CD4 þ T cells, only those T cells expressing Sle1a.1 or Sle1a. 2 showed enhanced activation and a decreased proportion of CD62L þ Tregs. Interestingly, the increased level of activation and decreased level of Tregs associated with the Sle1a sub-loci were exaggerated when assessed in the lymphopenic environment of the mixed BM chimera when compared with unmanipulated mice, as shown in Figures 4 and 5 . Taken together, we conclude that expression of either Sle1a.1 or Sle1a.2 results in T cell-intrinsic phenotypes. The abnormal phenotypes are not transferable to bystander normal T cells, excluding Sle1a.1 or Sle1a.2 being mediated through a soluble factor.
Discussion
Genome-wide linkage and association studies have shown that the genetic architecture of lupus is based on a large number of susceptibility genes, each of them with a modest size effect. 29 The results reported in this study showed that lupus susceptibility in the NZM2410 mouse fits this genetic model. Sle1, initially identified as the strongest quantitative traits loci linked to lupus nephritis, 3 is necessary for pathogenesis. 30 A congenic dissection revealed that Sle1 primary effect was a loss of tolerance to chromatin, which is considered to be an initiating event in the progression to autoimmune pathogenesis. 10, 31 Screening of Sle1 congenic recombinants for the production of anti-chromatin IgG initially identified three independent loci: Sle1a, Sle1b and Sle1c.
13
Sle1b corresponds to polymorphisms in four genes of the SLAM family: Slamf1, Slamf2, Slamf5 and Slamf6 (Ly108). 14 The differential expression of two splice isoforms in the Ly108 NZW allele results in the production of autoreactive B cells. 32 Further recombinant analyses revealed that Sle1c corresponds to at least two loci. 19 This study reveals that the Sle1a phenotypes also correspond to genetic variations in more than one gene. Overall, these results showed that Sle1 results from the combined effects of at least five genes.
As predicted by the model, each of the Sle1 sub-loci presents a weaker phenotype when compared with the entire locus, especially for Sle1a and Sle1c, for which the penetrance of anti-chromatin IgG was only approximately 30%. 13 An outcross with NZB has however shown that Sle1c contributed to autoimmune pathology. 23 In this study, the same strategy showed that Sle1a augments the production of anti-chromatin IgG in (NZW Â B6.Sle1a)F1 mice and anti-dsDNA IgG in both (NZW Â B6.Sle1a)F1 Sle1a regulation of T-cell function requires two sub-loci CM Cuda et al and (NZB Â B6.Sle1a)F1 mice. Furthermore, the cGVHD model showed that Sle1a expands the pool of ANAautoreactive B cells, and this was largely because of intrinsic Sle1a expression in B cells. This was matched by a high penetrance of ANA in B6.Sle1a mice. These results show that Sle1a, which has by itself a small individual autoimmune effect, contributes to the overall lupus phenotype. We performed a systematic assessment of the Sle1a phenotypes in the two Sle1a.1 and Sle1a.2 recombinants intervals that cover the entire Sle1a locus. The small potential overlap between Sle1a.1 and Sle1a.2 is unlikely to have a role as it does not contain any gene, and the message level of Pbx1, which is located downstream of the overlap, is similar between the NZW and B6 alleles (Cuda et al., unpublished) . The NZW allele of Fcgr2b in B6.Sle1a.2 affects germinal center formation, 26 but it is not involved in the phenotypes considered in this study as Sle1a expresses Fcgr2b B6 . The increased cGVHD response, as well as the increased T1/follicular B-cell ratio, mapped to Sle1a.2 and not Sle1a.1. This was not sufficient however to confer a highly penetrant ANA production, suggesting that Sle1a.2 directly increases the number of autoreactive B cells, but Sle1a.1 is also required for ANA production.
Mixed BM chimeras showed that both Sle1a.1 and Sle1a.2 increase CD4 þ T-cell activation and decreased Treg levels in an intrinsic manner, as we have previously shown for Sle1a.
18 Both loci also resulted in an increased spontaneous proliferation and activation of the CD4 þ T cells. However, only Sle1a.1 increased ICOS expression, which is critical for CD4 þ T cells for providing help to B cells, as well as for regulating T-cell tolerance. 33 A recent study has shown that ICOS controls CD4 þ T-cell inflammatory functions in the MRL/lpr model of lupus. 34 Our results suggest that Sle1a.1 has an important role in this process. Both Sle1a.1 and Sle1a.2 reduced the number of peripheral Tregs, but contrary to Sle1a, the in vitro suppressive functions of Sle1a.1 and Sle1a.2 Tregs were similar to that of B6 Tregs, except for a small reduction at low Treg/Teff ratios. The experimental colitis model showed that Sle1a.1, but not Sle1a.2, Tregs have diminished functions when compared with B6 Tregs, and that also Sle1a.1, but not Sle1a.2, Teffs were resistant to Treg suppression when compared with B6 Teffs. In fact, the effect of Sle1a.1 seemed greater on Teffs than on Tregs. Overall, both Sle1a.1 and Sle1a.2 expression affects Treg numbers and functions and contributes to the overall phenotype that we have reported for Sle1a. But if in vivo assays are better indicators of physiological functions, Sle1a.1 has a stronger effect on Treg functions and on the ability of Teffs to respond to Tregs.
We also showed that renal inflammation paralleled the colon inflammation in the experimental colitis model, strongly suggesting that the immunologic and inflammatory pathway involved in colitis and interstitial nephritis are similar and modified by the inherent differences in organ anatomy and functions. The histopathology and experimental design suggest a type IV hypersensitivity reaction for these responses. This further supported the contribution of T cell-mediated hypersensitivity response to the pathogenesis of lupus nephritis in some strains of lupus mice 35 and some sub-sets of clinical disease. 36 Our results show that Sle1a CD4
þ T cells show an enhanced capacity to induce renal injury, and suggest that this might be an additional pathway by which this locus contributes to lupus pathogenesis. The Sle1a.1 interval contains only one gene, Pbx1, whose expression has been reported in B cells and macrophages, 37 but not in normal CD4 þ T cells. 38 However, gene arrays have shown Pbx1 expression in murine and human T cells (Table 2 ). Sle1a.2 contains 15 known genes (Table 2) . We cannot predict at this time whether the Sle1a.2 B-cell and CD4 þ T-cell phenotypes result from polymorphisms in the same gene or two different genes. Among the Sle1a.2 genes, Sh2d1b encodes for Eat-2, a SAP (SLAM-associated protein) family adaptor of the SLAM genes, whose function is best understood in natural killer cells, 39 but is also expressed in B and T cells, and dendritic cells, in which it recruits Src kinases. 40 Given the strong epistasis between Sle1b, which corresponds to polymorphisms in SLAM family genes, 14 and Sle1a, 41 Sh2d1b should be considered as a strong candidate for Sle1a.2.
In summary, both Sle1a.1 and Sle1a.2 are necessary for the full expression of Sle1a phenotypes. Sle1a.1, and to a lesser extent Sle1a.2, significantly affects CD4 þ T-cell activation as well as Treg differentiation and function. Sle1a.2 also results in an increased production of autoreactive B cells. We did not observe major epistatic effects between Sle1a.1 and Sle1a.2, as many of their phenotypes were similar between Sle1a and at least one of the sub-loci. Interestingly, none of the genome-wide association studies in human lupus has identified so far any evidence of epistasis, but rather these studies have provided evidence that each genetic variant acts independently to increase disease susceptibility. 29 Our data suggest that Sle1a.1 and Sle1a.2 fit this model.
Materials and methods

Mice
B6. Sle1a
NZW/NZW (B6.Sle1a) mice were described as B6.Sle1a(15-353) 13 and B6.Sle1a.2 NZW/NZW (B6.Sle1a.2) mice as B6.Sle1(111-148). 42 The Sle1a.1 NZW/NZW (Sle1a.1) interval was obtained as a Sle1a recombinant (Figure 3 ). Genotyping with microsatellite markers was performed as previously described, 13 and single-nucleotide polymorphism genotyping was performed by direct sequencing. B6, NZB/BinJ (NZB), NZW/J, B6.129S7-Rag1 tm1Mom /J (B6.Rag), B6.129P2-Tcrb bm12 /KhEg (B6.bm12) mice were originally obtained from The Jackson Laboratory (Bar Harbor, ME, USA). Cohorts of female (NZB Â B6.Sle1a)F1, (NZW Â B6.Sle1a)F1, (NZB Â B6)F1 and (NZW Â B6)F1 hybrids were aged to 1 year. Female congenic mice and B6 matched controls were used at the age specified for each experiment. All mice were bred and maintained at the University of Florida in specific pathogen-free conditions. All experiments were conducted according to the protocols approved by the institutional animal care and use committee of the University of Florida.
Antibody measurements
Anti-dsDNA and anti-chromatin enzyme-linked immunosorbent assays were carried out as previously described. 31 Sera were tested in duplicate in a 1:100 dilution. Relative units were standardized using a positive serum from an NZM2410 mouse, arbitrarily setting the reactivity of a 1:100 dilution of this control serum to 100 units. cGVHD induction cGVHD was induced according to an established protocol. 43 In brief, 50-80 Â 10 6 B6.bm12 splenocytes were injected intraperitoneally into 9-month-old B6.Sle1a, B6.Sle1a.1, B6.Sle1a.2 or B6 mice (4-6 mice per strain). Serum was collected weekly up to 5 weeks after injection, when the mice were killed and flow cytometry was performed on splenocytes. The presence of immune complexes in the kidneys was evaluated on frozen sections stained with fluorescein isothiocyanate-conjugated anti-C3 (Cappel, Durham, NC, USA) and anti-IgG H þ L chains (Jackson Immunoresearch, West Grove, PA, USA). Staining intensity was evaluated in a blind manner on a semiquantitative 0-3 scale and averaged on at least 10 glomeruli per section. The experiments were performed twice. We also induced cGVHD in lethally irradiated B6 mice reconstituted with mixed BM from B6.Sle1a.Tcrb À/À .Tcrd 
Tcrd
À/À or B6.Igh6 (1:1 ratio) in such a way that the T-cell and B-cell origin was either from Sle1a or B6. B6.bm12 splenocytes were injected 2 months after BM reconstitution.
In vitro and in vivo assessment of Teff and Treg functions CD4 À (used as APC), CD4 þ CD25 À Teff, and CD4 þ CD25 þ Treg splenocytes were purified using the CD4 þ CD25 þ cell kit (Miltenyi Biotec, Auburn, CA, USA) to 490% purity. In vitro suppression assays were performed as previously described in the presence of 1 mg ml -1 anti-CD3. 20 The number of Teffs was kept constant at 5 Â 10 5 cells per well, whereas the number of Tregs was titrated in fourfold increments. To assess the suppressive function of T cells in vivo, 4 Â 10 5 CD4 þ CD25 À Teff from 6-month-old donors were transferred into 2-month-old B6.Rag mice in the presence or absence of 1 Â 10 5 Tregs as previously described. 20 The body weights of the injected mice were monitored weekly for up to 8 weeks. Mice that lost X15% of their body weight were killed. The colon was processed and longitudinal sections were stained with hematoxylin and eosin and periodic acid Schiff stains. The degree of inflammation was evaluated in two dimensions: one from the mucosa (lamina propria, epithelial crypts and muscularis mucosa) through the submucosa, muscularis propria (externa) and serosa, and the second along the longitudinal axis. The colons were assigned a rank score from least to most inflammation (one through n) where n was the total number of samples. Each kidney divided transversely at the midsection was processed and stained as for the colon. Interstitial inflammation was limited to the cortex with minimum extension into the outer stripe of the outer medulla. Inflammation was assessed by counting the number of inflammatory foci per cross-section of kidney. An inflammatory focus was defined as continuous inflammation involving X2 contiguous tubules and adjacent structures (glomeruli, vessels) if present.
BM chimeras
Chimeras were prepared as previously described. 12 In brief, 6-to 8-week-old lethally irradiated B6 mice were reconstituted with BM from B6.Thy1a and B6.Sle1a.1 or B6.Sle1a.2 mice in a 1:1 ratio. Flow cytometry was performed 8 weeks after reconstitution to evaluate T-cell activation and Treg levels. CD69 levels were measured 12 h after stimulation with anti-CD3 (1 mg ml -1 ) and anti-CD28 (0.5 mg ml -1 ).
Statistical analysis
Statistical analyses were performed using the GraphPad Prism 4 software. Unless indicated, graphs show median values for each group and nonparametric tests and multiple-test corrections were used as appropriate.
Comparisons for BM chimeras were made with paired two-tailed Student's t-tests. Each in vitro experiment was performed at least twice with reproducible results.
